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Study objective: To describe characteristics of postmenopausal women on long-term 
bisphosphonate therapy who fall into one of four fracture risk categories (low, mild, moderate, 
high), and to determine the prevalence of women eligible for a drug holiday.
Design: Retrospective electronic health record review.
Setting: Eight primary care clinics within a university-based health care system.
Patients: A total of 201 postmenopausal women of ages 55–89 years, with osteopenia or 
osteoporosis, prescribed bisphosphonate therapy for .4 years, between October 10, 2002 and 
September 9, 2012.
Main results: The patients’ mean age was 71.4 (±8.2) years; their mean body mass index was 
25.3 (±5.6) kg/m2; and 73.1% were white. Seventy-four out of 201 patients (36.8%) were low-
risk; 10/201 (5.0%) were mild-risk; 72/201 (35.8%) were moderate-risk; and 45/201 (22.4%) 
were high-risk. Eighty-one women (40.3%) were eligible for a drug holiday or discontinuation. 
The estimated drug cost avoided per eligible patient was $574.80. Calcium and/or vitamin D 
supplementation was documented in 52.7% of women.
Conclusion: More than one-third of postmenopausal women taking long-term bisphosphonate 
therapy had low fracture risk, and over 40% of our patients were eligible for a drug holiday or 
discontinuation. These data emphasize the need to accurately assess risk and benefit in patients 
treated with bisphosphonate therapy.
Keywords: postmenopausal osteoporosis, bisphosphonates, drug holiday, fracture
Introduction
Bisphosphonates are widely prescribed for the prevention and treatment of osteoporosis. 
As the prescribing of these drugs has increased over the past decade, multiple concerns 
have arisen regarding adverse effects, including osteonecrosis of the jaw and esopha-
geal cancer (though there have been conflicting data to support this association).1,2 The 
association of bisphosphonate therapy and atypical fracture continues to be a topic of 
investigation, with evidence demonstrating that longer duration of treatment is cor-
related with increased risk.3–5 Due to these potential adverse effects of bisphosphonate 
therapy, some experts have advocated for a period of time off therapy (or a “drug 
holiday”) for certain patients.6 As a result, proper patient selection for a drug holiday 
and appropriate treatment duration and implementation of a drug holiday continue to 
be topics of uncertainty.
In September 2011, after the US Food and Drug Administration (FDA) evaluated 
the long-term efficacy and safety data for bisphosphonates, a recommendation was 
made to provide clarification, on the package insert labeling, about the duration of 
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bisphosphonate therapy.7,8 However, the FDA  committee 
could not come to a consensus regarding a specif ic 
recommendation. Consequently, the following statement 
is now listed on bisphosphonate package labeling: “The 
optimal duration of use has not been determined. The need 
for continued therapy should be re-evaluated on a periodic 
basis.” In response to the FDA committee, the American 
Association of Clinical Endocrinologists recommends main-
taining current practice with bisphosphonate therapy until 
the FDA comes to a final consensus on treatment duration.9 
In the 2013 Clinician’s Guide to Prevention and Treatment of 
Osteoporosis, the National Osteoporosis Foundation recog-
nized that there is limited evidence to guide the duration of 
treatment. It stated that those at modest risk of fracture may 
have bisphosphonate therapy discontinued after 3–5 years, 
while continuation of treatment should be considered in 
those with high fracture risk.10
Based on expert opinion, the need for, and duration of 
a drug holiday are related both to treatment duration and 
to fracture risk. Diab and Watts suggested different drug 
holiday durations, based on assessment of patient-specific 
fracture risk (mild, moderate, or high). For those with 
mildly increased risk, the authors recommend treatment 
for approximately 5 years, with a drug holiday until bone 
mineral density (BMD) decreases significantly or fracture 
occurs. For those with moderately increased risk, the authors 
recommend treatment for 5–10 years, with a 2–3 year drug 
holiday. For high-risk patients, treatment for 10 years, fol-
lowed by a 1–2 year drug holiday, was recommended.11 The 
definitions of what constituted mild, moderate, and high risk 
were not discussed.
To the best of our knowledge, there is no literature avail-
able that provides criteria for fracture risk categorization, or 
the percentage of patients who will typically fall into these 
risk categories and ultimately, be potential candidates for a 
drug holiday. The aims of this study were to describe the frac-
ture risk of postmenopausal women on long-term bisphos-
phonate therapy in primary care, identify postmenopausal 
women who could be potential candidates for a drug holiday 
or discontinuation, estimate potential drug cost avoidance, 
and describe documentation for calcium and vitamin D 
supplementation taken by postmenopausal women on long-
term bisphosphonate therapy.
Methods
study design and patient population
This retrospective, observational medical record review was 
approved by the Colorado Multiple Institutional Review 
Board. Electronic health records (EHRs) from eight primary 
care clinics within the University of Colorado Health system 
were screened to determine eligible patients. Included in 
the study were women aged 55–89 years old (or younger, 
with a diagnosis of postmenopause), who had at least 
4 years of documented, continuous bisphosphonate therapy 
(alendronate, ibandronate, risedronate, or zoledronic acid), 
and with diagnoses of osteopenia or osteoporosis. Women 
were excluded if they received treatment with a bisphospho-
nate for an indication other than osteoporosis or osteopenia 
(eg, Paget’s disease, hypercalcemia of malignancy).
Primary and secondary outcomes
The primary outcome of the study was to determine the 
prevalence of women in the four fracture risk categories 
(low, mild, moderate, and high), at the time of their last use 
of bisphosphonate, as documented in the EHR. Risk cat-
egorization was determined by the presence of osteoporosis 
or osteopenia and the number of risk factors for fracture at 
the date of last documented bisphosphonate use (Table 1).12 
Women with a history of fragility fracture were placed in 
the high-risk category.
Secondary outcomes of the study included the preva-
lence of postmenopausal women with known treatment 
duration of bisphosphonates who may be eligible for 
a drug holiday, the estimated drug cost avoidance for 
Table 1 Fracture risk categorization criteria, treatment duration, and drug holiday duration
Risk category Diagnosis Number of  
risk factorsa
Treatment  
duration
Drug holiday
low Osteopeniab 0–2 not indicated n/a
Mild Osteopeniab .2 5 years Until fracture or significant 
decrease in BMD
Moderate Osteoporosisc 0–2 5–10 years 2–3 years
Highd Osteoporosisc .2 10 years 1–2 years
Notes: aage $70 years old; corticosteroid use of $5 mg prednisone or equivalent for $3 months ever; $3 alcohol drinks/day; low BMI (defined as ,18 kg/m2); parental 
history of hip fracture; white or asian race; secondary osteoporosis, rheumatoid arthritis;12 bdefined as most recent T-score between -1 and -2.5; cdefined as most recent 
T-score at or below -2.5; dwomen with history of fragility fracture, categorized as high-risk.
Abbreviations: n/a, not applicable; BMD, bone mineral density; BMI, body mass index.
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postmenopausal women when eligible for a drug holiday, 
and determination of the rate of accurate documentation for 
calcium and vitamin D taken by postmenopausal women on 
long-term bisphosphonate therapy. Criteria for drug holi-
days, based on recommended duration of therapy, can be 
seen in Table 1. Low-risk patients were considered eligible 
for drug discontinuation because they were likely placed 
on bisphosphonate therapy inappropriately (ie, low-risk 
patients would not meet criteria for initiating treatment 
based on FRAX® scoring [the World Health Organization’s 
fracture risk assessment tool]).
Data collection and analysis
Drug cost avoidance data were determined based on a 
monthly cost of alendronate 70 mg weekly.13 Given that 
low-risk patients are candidates for drug discontinuation, all 
months of treatment in low-risk patients were considered for 
drug cost avoidance. For mild risk, any months of treatment 
beyond 5 years were considered for drug cost saving, and 
any months after 10 years were considered for moderate- and 
high-risk patients. Calcium and vitamin D documentation 
was determined by the presence of these supplements in the 
patient’s medication list at the date of the last documented 
bisphosphonate prescription.
Data were extracted from the EHR, using the inclusion cri-
teria as parameters, to produce a list of women to be evaluated. 
All women initially extracted from this list were verified for 
inclusion through individual patient reviews. International 
Classification of Diseases, 9th Revision, Clinical  Modification 
(ICD-9-CM) codes were used to identify patients with 
osteoporosis (code 733.0X). To identify osteopenic patients, 
“osteopenia” was searched in the patient’s problem list within 
the EHR. These diagnoses were then confirmed using dual-
energy X-ray absorptiometry (DXA) scan results, for each 
patient who met study criteria. Women without documentation 
of a DXA scan were not included in the analysis, because their 
diagnosis could not be verified. Exclusion criteria were evalu-
ated on an individual patient basis, once the list was created. 
For generation of the initial report, women with .2 years of 
continuous therapy (rather than 4 years) were selected, to ensure 
that the greatest number of patients could be included.
Data were collected describing patient demographics, risk 
factors for fracture, bisphosphonate medication, duration, and 
indication, DXA scan results, and calcium and vitamin D 
supplementation. These data were analyzed using descrip-
tive statistics, which included means with standard deviation 
(SD), frequencies (actual and percentage), and estimation of 
cost avoidance, where appropriate.
Results
There were 372 women who met age and diagnosis require-
ments and who had .2 years of bisphosphonate therapy. 
Of these, 147 women were excluded for having ,4 years 
of continuous therapy, and 24 were excluded for  having 
no DXA scan documented in their EHR. A total of 
201 patients met all study criteria and were included in the 
Table 2 Demographics
Low-risk 
(n=74)
Mild-risk 
(n=10)
Moderate-risk 
(n=72)
High-risk 
(n=45)
Total 
(n=201)
age 
 Mean ± sD, (range)
 
69.3±7.4 (57–89)
 
74.3±4.1 (70–82)
 
70.3±7.7 (56–88)
 
75.9±9.0 (55–89)
 
71.4±8.2 (55–89)
BMI 
 Mean ± sD, (range)
 
26.3±5.5 (17.8–42.0)
 
24.3±5.6 (16.1–34.3)
 
24.2±4.7 (17.1–39.3)
 
25.6±6.9 (14.3–46.8)
 
25.3±5.6 (14.3–46.8)
Treatment duration (months) 
Mean ± sD, (range)* 70.2±11.7 (49–93) 69.6±14.3 (50–86) 69.4±11.5 (48–87) 72.0±12.6 (48–87) 70.3±11.9 (48–93)
race, n (%)
 asian 6 (8.1) 0 (0) 13 (18.1) 2 (4.4) 21 (10.4)
 Black 4 (5.4) 0 (0) 3 (4.2) 1 (2.2) 8 (4.0)
 White 58 (78.4) 10 (100) 44 (61.1) 35 (77.8) 147 (73.1)
 Other/unknown 6 (8.1) 0 (0) 12 (16.7) 7 (15.6) 25 (12.4)
Medications, n (%)
 alendronate 48 (64.9) 9 (90.0) 47 (65.3) 30 (66.7) 134 (66.7)
 Ibandronate 3 (4.1) 0 (0) 0 (0) 3 (6.7) 6 (3.0)
 risedronate 5 (6.8) 1 (10.0) 12 (16.7) 6 (13.3) 24 (11.9)
 Zoledronic acid 2 (2.7) 0 (0) 0 (0) 0 (0) 2 (1.0)
 Two of the above 14 (18.9) 0 (0) 13 (18.1) 6 (13.3) 33 (16.4)
 Three of the above 2 (2.7) 0 (0) 0 (0) 0 (0) 2 (1.0)
Note: *The exact start date was unknown for 123/201 (61.2%) of women.
Abbreviations: sD, standard deviation; BMI, body mass index.
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analysis. Demographic information is presented in Table 2. 
The mean age was 71.4 years. The mean duration of  documented 
bisphosphonate therapy was 70.3 months. The mean age was 
highest in high-risk patients (75.9 years) and lowest in low-
risk patients (69.3 years). Most patients were white (73.1%). 
The average body mass index was 25.3 kg/m2. The majority 
of patients (66.7%) were prescribed alendronate. The exact 
start date of bisphosphonate therapy was unknown for 123 of 
the 201 women (61.2%). None of the women were prescribed 
more than one bisphosphonate at a time, but 35/201 (17.4%) 
were prescribed more than one different bisphosphonate dur-
ing their treatment period.
For the primary outcome of fracture risk categorization, 
74/201 (36.8%) were low-risk; 10/201 (5.0%) were mild-risk; 
72/201 (35.8%) were moderate-risk; and 45/201 (22.4%) 
were high-risk (Figure 1). No patients had 10 years of docu-
mented therapy. As a result, drug eligibility and discontinua-
tion was only determined in the low- and mild-risk patients. 
Three of the 10 mild-risk patients did not qualify for a drug 
holiday due to having ,5 years of treatment. Combining the 
74 low-risk patients and 7 of 10 eligible mild-risk patients 
resulted in 81/201 (40.3%) of the total population being 
eligible for a drug holiday or discontinuation (Table 3).
The 74 low-risk patients had a combined treatment dura-
tion of 5,198 months. The 7 mild-risk patients eligible for 
a drug holiday had a total 123 months of therapy beyond 
5 years. This resulted in 5,321 months of therapy eligible for 
drug cost avoidance. A cost of $2.02 for a 70 mg alendronate 
tablet resulted in a total cost of $105.04 for 52 weeks of 
treatment, which was converted to monthly cost of approxi-
mately $8.75.13 Multiplying 5,321 eligible months by the 
$8.75 monthly cost of alendronate gave a total cost avoidance 
of $46,558.75, or $574.80 per eligible woman (Table 3).
Documentation of both calcium and vitamin D 
supplementation was noted for 106/201 (52.7%) of the total 
population (Table 4). Calcium only was documented in 
10/201 (5.0%) of women; vitamin D only was documented 
in 30/201 (14.9%); neither supplement was documented in 
55/201 (27.4%) of women. Although it was not established 
a priori, the time between date of last documented bisphos-
phonate use and most recent DXA scan was evaluated. Of the 
total population, 56/201 (27.9%) had .24 months elapsed 
without a DXA scan, and 45/201 (22.4%) had .30 months 
elapsed since their last DXA scan.
Discussion
This study revealed that patient-specific fracture risk evalu-
ation could be performed to identify patients as low-, mild-, 
moderate-, or high-risk. Based on expert opinion and pre-
viously published studies, we established criteria for low, 
mild, moderate, and high fracture risk. We believe these 
criteria accurately reflect fracture risk in the postmenopausal 
population, and are generalizable. More than one-third of the 
patient population was considered low-risk for fracture. It 
was found that 40.3% of women may be eligible for a drug 
holiday or drug discontinuation. This analysis provided a 
description of postmenopausal women on long-term bisphos-
phonate therapy, which has not been previously available in 
current literature.
Due to a change in the EHR system at the study institu-
tion, medical record data prior to 2005 were not available. 
This is the main reason for exact start dates of bisphospho-
nate therapy being unknown in 123/201 (61.2%) of women. 
Additionally, any woman who entered the system after 2005, 
while already on bisphosphonate therapy, did not have a start 
date clearly identified. As a result, the potential for a drug 
Mild
10/201 (5.0%)
Low
74/201 (36.8%)
High
45/201 (22.4%)
Moderate
72/201 (35.8%)
Figure 1 Primary outcome results: risk category (n, %).
Table 3 Drug holiday eligibility and estimated drug cost avoidance
Low-risk 
(n=74)
Mild-risk 
(n=10)
Total (low and 
mild) (n=84)
number of patients  
eligible (% of total  
population)
74 (36.8%) 7 (3.5%) 81 (40.3%)
cumulative number of  
treatment months eligible  
for drug cost avoidance
5,198 123 5,321
estimated drug cost  
avoidance
$45,482.50 $1,076.25 $46,558.75
estimated drug cost 
avoidance/patient
$614.63 $153.75 $574.80
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holiday was not evaluated in the moderate- and high-risk 
groups, because 10 years of data were not available. Overall, 
the duration of therapy is likely to be an underestimation. It 
is most reasonable to assume that known start dates would 
have extended the average treatment duration of this patient 
population. It is likely this would result in more patients 
being eligible for drug holidays, and in greater potential 
drug cost avoidance.
While some patients were on brand name bisphospho-
nates, estimated drug cost avoidance was determined using 
generic alendronate, as the most conservative approach. 
Approximately $46,000 in drug cost avoidance was estimated 
in the 201 patients included in this study. One study estimated 
that approximately 34.5 million Americans have osteopenia 
and another estimated that 49% of adults .50 years old in 
the USA have low bone mass at the lumbar spine or femoral 
neck.14,15 Consequently, it is possible that application of this 
analysis nationwide has the potential to result in significant 
drug cost avoidance.
Calcium and vitamin D supplementation was documented 
in approximately half of the total population. Recent studies 
have reported documentation rates of 16%–91% for patients 
taking bisphosphonates.16,17 Although the rates in this analysis 
may be an underestimation of true calcium and vitamin D 
use in this population, due to possible incomplete medication 
lists in the EHR, they suggest suboptimal supplementation 
use. Considering the importance of these supplements to 
bone health, prescribing and documentation would ideally 
occur in a larger percentage of women.
The general recommendation for frequency of DXA scans 
in this postmenopausal population is every 2 years, though 
more frequent testing could be done in certain situations 
and/or high-risk patients.18 The cutoff of .30 months since 
last DXA was also evaluated, as it may not be reasonable for 
a DXA scan to be done exactly every 2 years. Serial BMD 
measurements are of importance in this population, as testing 
can monitor response as well as guide the need for reassess-
ment of treatment.
Additional limitations of this study are its setting in 
one health care system and its retrospective design. The 
use of only eight primary care clinics limited the number 
of patients included in the study. Retrospective analysis 
relies on accurate documentation. Information relating to 
risk factors (eg, parental hip fracture) may not be known or 
documented in an appropriate manner to collect during chart 
review. Additionally, clinical judgment was used to deter-
mine if a fracture was due to fragility, in situations where 
documentation was unclear.
This analysis was also performed under the assumption 
that medication reconciliation is being conducted at every 
office visit to assure accuracy of medication lists. Therefore, 
it was also assumed that each woman was taking a medica-
tion if it was prescribed and listed on her medication list. 
Unfortunately, this data collection could not be tied to a 
claims database, which could verify medication adherence.
The risk factors used in this analysis are similar to those 
used for the FRAX fracture risk assessment tool.19 It would 
not be very likely for a low-risk patient (eg, osteopenia 
with 0–2 risk factors) to qualify for treatment by the FRAX 
 calculation. However, the FRAX calculation was not used in 
this analysis, as its use is not validated in patients currently 
receiving treatment. Since risk factors must be present in a 
“yes or no” manner, a specific age cutoff had to be used for 
the risk factor of elderly age. The authors of this study felt that 
available literature supported the use of 70 years of age as a 
cutoff for increased risk of fracture.20 A potential limitation, 
although unlikely, is that an elderly, low-risk woman could 
meet appropriate treatment criteria by the FRAX calculation, 
with age alone driving their increased risk for fracture.
Conclusion
This analysis highlights the need to accurately assess patient-
specific risk factors prior to initiation of therapy, to determine 
fracture risk. Our novel approach clearly establishes criteria for 
low, mild, moderate, and high fracture risk. This assessment 
has the potential to identify overuse of bisphosphonates, by 
identifying a large proportion of women at low risk of fracture. 
This could result in a significant drug cost avoidance for 
patients on long-term bisphosphonate therapy. It also allows 
for appropriate assessment of patients who may need to remain 
Table 4 calcium and vitamin D documentation
Supplement  
documentation
Low-risk (n=74) 
n (%)
Mild-risk (n=10) 
n (%)
Moderate-risk (n=72) 
n (%)
High-risk (n=45) 
n (%)
Total (n=201) 
n (%)
calcium only 2 (2.7) 2 (20.0) 3 (4.2) 3 (6.7) 10 (5.0)
Vitamin D only 13 (17.6) 1 (10.0) 10 (13.9) 6 (13.3) 30 (14.9)
calcium and vitamin D 33 (44.6) 6 (60.0) 43 (59.7) 24 (53.3) 106 (52.7)
neither 26 (35.1) 1 (10.0) 16 (22.2) 12 (26.7) 55 (27.4)
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on therapy, and who require a longer duration of treatment. 
Lastly, this analysis highlights suboptimal use of calcium and 
vitamin D, and frequency of DXA scans, which need to be 
accurately documented in the patient health care record.
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